156 related articles for article (PubMed ID: 17603023)
1. Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity.
Vermeire K; Lisco A; Grivel JC; Scarbrough E; Dey K; Duffy N; Margolis L; Bell TW; Schols D
Biochem Pharmacol; 2007 Aug; 74(4):566-78. PubMed ID: 17603023
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues.
Bell TW; Anugu S; Bailey P; Catalano VJ; Dey K; Drew MG; Duffy NH; Jin Q; Samala MF; Sodoma A; Welch WH; Schols D; Vermeire K
J Med Chem; 2006 Feb; 49(4):1291-312. PubMed ID: 16480266
[TBL] [Abstract][Full Text] [Related]
3. Unsymmetrical cyclotriazadisulfonamide (CADA) compounds as human CD4 receptor down-modulating agents.
Demillo VG; Goulinet-Mateo F; Kim J; Schols D; Vermeire K; Bell TW
J Med Chem; 2011 Aug; 54(16):5712-21. PubMed ID: 21800875
[TBL] [Abstract][Full Text] [Related]
4. Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.
Vermeire K; Schols D
J Antimicrob Chemother; 2005 Aug; 56(2):270-2. PubMed ID: 15980096
[TBL] [Abstract][Full Text] [Related]
5. Improving potencies and properties of CD4 down-modulating CADA analogs.
Bell TW; Demillo VG; Schols D; Vermeire K
Expert Opin Drug Discov; 2012 Jan; 7(1):39-48. PubMed ID: 22468892
[TBL] [Abstract][Full Text] [Related]
6. [Cyclotriazadisulfonamides as new and unique HIV entry inhibitors].
Vermeire K
Verh K Acad Geneeskd Belg; 2007; 69(5-6):231-47. PubMed ID: 18351208
[TBL] [Abstract][Full Text] [Related]
7. Syntheses and anti-HIV and human cluster of differentiation 4 (CD4) down-modulating potencies of pyridine-fused cyclotriazadisulfonamide (CADA) compounds.
Lumangtad LA; Claeys E; Hamal S; Intasiri A; Basrai C; Yen-Pon E; Beenfeldt D; Vermeire K; Bell TW
Bioorg Med Chem; 2020 Dec; 28(24):115816. PubMed ID: 33181479
[TBL] [Abstract][Full Text] [Related]
8. The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor.
Vermeire K; Bell TW; Choi HJ; Jin Q; Samala MF; Sodoma A; De Clercq E; Schols D
Mol Pharmacol; 2003 Jan; 63(1):203-10. PubMed ID: 12488553
[TBL] [Abstract][Full Text] [Related]
9. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor.
Vermeire K; Brouwers J; Van Herrewege Y; Le Grand R; Vanham G; Augustijns P; Bell TW; Schols D
Curr HIV Res; 2008 May; 6(3):246-56. PubMed ID: 18473788
[TBL] [Abstract][Full Text] [Related]
10. Specific CD4 down-modulating compounds with potent anti-HIV activity.
Vermeire K; Schols D
J Leukoc Biol; 2003 Nov; 74(5):667-75. PubMed ID: 12960237
[TBL] [Abstract][Full Text] [Related]
11. Novel anti-HIV cyclotriazadisulfonamide derivatives as modeled by ligand- and receptor-based approaches.
Pinheiro JR; Bitencourt M; da Cunha EF; Ramalho TC; Freitas MP
Bioorg Med Chem; 2008 Feb; 16(4):1683-90. PubMed ID: 18053727
[TBL] [Abstract][Full Text] [Related]
12. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.
Van Herrewege Y; Morellato L; Descours A; Aerts L; Michiels J; Heyndrickx L; Martin L; Vanham G
J Antimicrob Chemother; 2008 Apr; 61(4):818-26. PubMed ID: 18270220
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
[TBL] [Abstract][Full Text] [Related]
14. New bis(thiosemicarbazonate) gold(III) complexes inhibit HIV replication at cytostatic concentrations: potential for incorporation into virostatic cocktails.
Fonteh PN; Keter FK; Meyer D
J Inorg Biochem; 2011 Sep; 105(9):1173-80. PubMed ID: 21708102
[TBL] [Abstract][Full Text] [Related]
15. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor.
Vermeire K; Zhang Y; Princen K; Hatse S; Samala MF; Dey K; Choi HJ; Ahn Y; Sodoma A; Snoeck R; Andrei G; De Clercq E; Bell TW; Schols D
Virology; 2002 Oct; 302(2):342-53. PubMed ID: 12441078
[TBL] [Abstract][Full Text] [Related]
16. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein.
Li H; Song H; Heredia A; Le N; Redfield R; Lewis GK; Wang LX
Bioconjug Chem; 2004; 15(4):783-9. PubMed ID: 15264865
[TBL] [Abstract][Full Text] [Related]
17. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
[TBL] [Abstract][Full Text] [Related]
18. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-HIV activity of alkylated quinoline 2,4-diols.
Ahmed N; Brahmbhatt KG; Sabde S; Mitra D; Singh IP; Bhutani KK
Bioorg Med Chem; 2010 Apr; 18(8):2872-9. PubMed ID: 20350812
[TBL] [Abstract][Full Text] [Related]
20. Anti-HIV-1 activity of propolis in CD4(+) lymphocyte and microglial cell cultures.
Gekker G; Hu S; Spivak M; Lokensgard JR; Peterson PK
J Ethnopharmacol; 2005 Nov; 102(2):158-63. PubMed ID: 16046088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
